strikeforce
Member
Treatment with Genentech‘s FDA-approved Esbriet (pirfenidone) has been shown in two independent studies to improve moderate to more severe lung function impairment in patients with idiopathic pulmonary fibrosis (IPF).
According to the presentation titled “Effect of Pirfenidone on Breathlessness as Measured by the UCSD-SOBQ Score in Patients with Idiopathic Pulmonary Fibrosis (IPF) with Moderate Lung Function Impairment,” Esbriet can reduce breathlessness in IPF patients with moderate lung function impairment compared to the placebo.
https://pulmonaryfibrosisnews.com/2017/05/24/latest-studies-support-esbriet-ipf-patients-more-severe-lung-function-impairment/
According to the presentation titled “Effect of Pirfenidone on Breathlessness as Measured by the UCSD-SOBQ Score in Patients with Idiopathic Pulmonary Fibrosis (IPF) with Moderate Lung Function Impairment,” Esbriet can reduce breathlessness in IPF patients with moderate lung function impairment compared to the placebo.
https://pulmonaryfibrosisnews.com/2017/05/24/latest-studies-support-esbriet-ipf-patients-more-severe-lung-function-impairment/